Ubs Asset Management Americas Inc Altimmune, Inc. Transaction History
Ubs Asset Management Americas Inc
- $417 Billion
- Q4 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Altimmune, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 92,392 shares of ALT stock, worth $523,862. This represents 0.0% of its overall portfolio holdings.
Number of Shares
92,392
Previous 79,266
16.56%
Holding current value
$523,862
Previous $486,000
37.04%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding ALT
# of Institutions
203Shares Held
37.6MCall Options Held
2MPut Options Held
1.69M-
Black Rock Inc. New York, NY5.32MShares$30.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.41MShares$25 Million0.0% of portfolio
-
State Street Corp Boston, MA3.39MShares$19.2 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA2.75MShares$15.6 Million0.89% of portfolio
-
Geode Capital Management, LLC Boston, MA1.71MShares$9.67 Million0.0% of portfolio
About Altimmune, Inc.
- Ticker ALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,025,300
- Market Cap $278M
- Description
- Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...